Pfizer’s Xeljanz pill has been approved in the US in psoriatic arthritis, for people who have not responded to, or cannot take, other disease-modifying drugs. Xeljanz has been FDA-approved since ...
Xeljanz woes are likely to be boost to Rinvoq, which is already growing fast – making $450 million in the first nine months of 2020, including $215 million in the third quarter alone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback